DexCom, Inc. vs Merck & Company, Inc. — Stock Comparison

DXCM
DexCom, Inc.
$61.35
▲ 3.02%
vs
MRK
Merck & Company, Inc.
$112.16
▲ 2.73%
Q·Score Winner
DexCom, Inc.
DXCM8.8/10vs 6.7/10

Q·Score Breakdown

8.8
Very Bullish
Overall
6.7
Neutral
8.5
Quality
6.2
9.1
Health
7
8.9
Growth
6.2
9.2
Valuation
7.2
8.4
Sentiment
7.1
DXCM

Consensus analyst target of $83.92 is 37% above current price.

MRK

Forward P/E of 11.5× is low relative to sector peers.

Analyst Consensus

BUY
Target $83.92 (+36.8%)
24 analysts
BUY
Target $129.74 (+15.7%)
27 analysts

Fundamentals

DXCM
MRK
26.3×
Trailing P/E
31.5×
20.1×
Forward P/E
11.5×
19.3%
Profit Margin
13.6%
61.5%
Gross Margin
76.6%
35.6%
ROE
15.0%
Revenue Growth
4.9%
91.9%
Earnings Growth
Beta
0.28
Price / Book
$23.7B
Market Cap
$277.0B
$54 – $90
52-Week Range
$73 – $125

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →